Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology

Carla Valéria de Alvarenga Antunes, Abrahão Elias Hallack Neto, Cristiano Rodrigo de Alvarenga Nascimento, Liliana Andrade Chebli, Ivana Lúcia Damásio Moutinho, Bruno do Valle Pinheiro, Maycon Moura Reboredo, Carla Malaguti, Antonio Carlos Santana Castro, Júlio Maria Fonseca Chebli, Carla Valéria de Alvarenga Antunes, Abrahão Elias Hallack Neto, Cristiano Rodrigo de Alvarenga Nascimento, Liliana Andrade Chebli, Ivana Lúcia Damásio Moutinho, Bruno do Valle Pinheiro, Maycon Moura Reboredo, Carla Malaguti, Antonio Carlos Santana Castro, Júlio Maria Fonseca Chebli

Abstract

Anemia is common in inflammatory bowel disease (IBD). However, epidemiological studies of nonwestern IBD populations are limited and may be confounded by demographic, socioeconomic, and disease-related influences. This study evaluated the prevalence, risk factors, and etiology of anemia in Brazilian outpatients with IBD.

Methods: In this cross-sectional study, 100 Crohn's disease (CD) patients and 100 ulcerative colitis (UC) subjects were assessed. Anemia workup included complete blood count, ferritin, transferrin saturation, serum levels of folic acid and vitamin B12, and C-reactive protein (CRP) concentration.

Results: The overall prevalence of anemia in IBD was 21%. There was no significant difference in the prevalence of anemia between CD subjects (24%) and UC (18%). Moderate disease activity (OR: 3.48, 95% CI, 1.95-9.64, P = 0.002) and elevated CRP levels (OR: 1.8, 95% CI, 1.04-3.11, P = 0.02) were independently associated with anemia. The most common etiologies of anemia found in both groups were iron deficiency anemia (IDA; 10% on CD and 6% on UC) followed by the anemia of chronic disease (ACD; 6% for both groups).

Conclusions: In Brazilian IBD outpatients, anemia is highly concurrent condition. Disease moderate activity as well as increased CRP was strongly associated with comorbid anemia. IDA and/or ACD were the most common etiologies.

References

    1. Kulnigg S., Gasche C. Systematic review: managing anaemia in Crohn's disease. Alimentary Pharmacology and Therapeutics. 2006;24(11-12):1507–1523. doi: 10.1111/j.1365-2036.2006.03146.x.
    1. de Souza G. S., Vidigal F. M., Chebli L. A., et al. Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients. Medical Science Monitor. 2013;19(1):716–722. doi: 10.12659/MSM.889196.
    1. Gasche C. Anemia in IBD: the overlooked villain. Inflammatory Bowel Diseases. 2000;6(2):142–150. doi: 10.1097/00054725-200005000-00013.
    1. Høivik M. L., Reinisch W., Cvancarova M., Moum B. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Alimentary Pharmacology and Therapeutics. 2014;39(1):69–76. doi: 10.1111/apt.12541.
    1. Guagnozzi D., Lucendo A. J. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World Journal of Gastroenterology. 2014;20(13):3542–3551. doi: 10.3748/wjg.v20.i13.3542.
    1. Gasche C., Berstad A., Befrits R., et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflammatory Bowel Diseases. 2007;13(12):1545–1553. doi: 10.1002/ibd.20285.
    1. Wells C. W., Lewis S., Barton J. R., Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflammatory Bowel Diseases. 2006;12(2):123–130. doi: 10.1097/01.MIB.0000196646.64615.db.
    1. Gisbert J. P., Bermejo F., Pajares R., et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflammatory Bowel Diseases. 2009;15(10):1485–1491. doi: 10.1002/ibd.20925.
    1. Liu K., Kaffes A. J. Iron deficiency anaemia: a review of diagnosis, investigation and management. European Journal of Gastroenterology and Hepatology. 2012;24(2):109–116. doi: 10.1097/MEG.0b013e32834f3140.
    1. Befrits R., Wikman O., Blomquist L., et al. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scandinavian Journal of Gastroenterology. 2013;48(9):1027–1032. doi: 10.3109/00365521.2013.819442.
    1. Gomollón F., Gisbert J. P. Anemia and inflammatory bowel diseases. World Journal of Gastroenterology. 2009;15(37):4659–4665. doi: 10.3748/wjg.15.4659.
    1. Wilson A., Reyes E., Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. The American Journal of Medicine. 2004;116(7) supplement 1:44–49. doi: 10.1016/j.amjmed.2003.12.011.
    1. Bergamaschi G., di Sabatino A., Albertini R., et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment. Haematologica. 2010;95(2):199–205. doi: 10.3324/haematol.2009.009985.
    1. Ott C., Scholmerich J. Extraintestinal manifestations and complications in IBD. Nature Reviews Gastroenterology & Hepatology. 2013;10(10):585–595. doi: 10.1038/nrgastro.2013.117.
    1. Silverberg M. S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. The Canadian Journal of Gastroenterology. 2005;19:5A–36A.
    1. Truelove S. C., Witts L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal. 1955;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041.
    1. World Health Organization. Report. WHO/NHP/01.3. Geneva, Switzerland: World Health Organization; 2011. Iron deficiency anemia assessment, prevention and control. A guide for programme managers.
    1. Filmann N., Rey J., Schneeweiss S., et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflammatory Bowel Diseases. 2014;20(5):936–945. doi: 10.1097/01.MIB.0000442728.74340.fd.
    1. Bager P., Befrits R., Wikman O., et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scandinavian Journal of Gastroenterology. 2011;46(3):304–309. doi: 10.3109/00365521.2010.533382.
    1. Gisbert J. P., Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. The American Journal of Gastroenterology. 2008;103(5):1299–1307. doi: 10.1111/j.1572-0241.2008.01846.x.
    1. Alves R. A., Miszputen S. J., Figueiredo M. S. Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables. Sao Paulo Medical Journal. 2014;132(3):140–146. doi: 10.1590/1516-3180.2014.1323568.
    1. Schreiber S., Howaldt S., Schnoor M., et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. The New England Journal of Medicine. 1996;334(10):619–623. doi: 10.1056/NEJM199603073341002.
    1. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of Clinical Investigation. 2004;113(9):1271–1276. doi: 10.1172/JCI200420945.
    1. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. Journal of Interferon & Cytokine Research. 1998;18(8):555–559. doi: 10.1089/jir.1998.18.555.
    1. Lewis J. D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817–1826. doi: 10.1053/j.gastro.2010.11.058.
    1. Leifert J. A. Anaemia and cigarette smoking. International Journal of Laboratory Hematology. 2008;30(3):177–184. doi: 10.1111/j.1751-553X.2008.01067.x.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner